On January 5, 2021 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, reported that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021 (Press release, Xenetic Biosciences, JAN 5, 2021, View Source [SID1234573468]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and accessible on the IR Calendar page of the Investors section of the Company’s website (xeneticbio.com).

On January 5, 2021 Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported that Bill Newell, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, Jan. 14, 2021 at 5:20 p.m. ET / 2:20 p.m. PT (Press release, Sutro Biopharma, JAN 5, 2021, View Source [SID1234573467]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. A replay of the webcast will be available for approximately 30 days following the event.

On January 5, 2021 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported that management will provide an overview of the company’s business strategy and development-stage programs at three upcoming virtual investor conferences (Press release, Spectrum Pharmaceuticals, JAN 5, 2021, View Source [SID1234573466]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect Conference, a fireside chat will be available on-demand through the conference portal and on the Spectrum corporate website beginning Monday, January 11th at 6 a.m. ET.
ICR Conference 2021, presentation, live webcast, Thursday, January 14th at 1:45 p.m. ET.
B. Riley Oncology Investor Conference, fireside chat, live webcast, Thursday, January 21st at 1 p.m. ET.
These events will be available from the Investor Relations section of the company’s website at View Source An archived webcast will be available shortly after the ICR and B. Riley live events from the same website location.

On January 5, 2021 Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, reported that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the H.C. Wainwright 2021 BioConnect Virtual Conference taking place January 11-14, 2021 (Press release, Sierra Oncology, JAN 5, 2021, View Source [SID1234573465]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available online beginning at 6:00 am ET on Monday, January 11, 2021 via the below link. A replay of the presentation will be available following the conference on the Investors section of Sierra’s corporate website in the Events & Webcast tab.

Presentation Link: View Source

On January 5, 2021 Labcorp (NYSE: LH), a leading global life sciences company, reported that members of the executive management team will participate in a virtual fireside chat at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12 at 8:20 a.m. (EST) (Press release, LabCorp, JAN 5, 2021, View Source [SID1234573464]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available via the Company website at www.Labcorp.com and archived for replay.